Search Results - "Sanchez Lorenzo, Luisa"

A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial by Gonzalez Martin, Antonio, Sanchez Lorenzo, Luisa, Colombo, Nicoletta, dePont Christensen, René, Heitz, Florian, Meirovitz, Mihai, Selle, Frederic, van Gorp, Toon, Alvarez, Nuria, Sanchez, Javier, Marqués, Carmen

“…Platinum based chemotherapy is the treatment of choice for ovarian cancer patients with a platinum treatment free interval of >6 months. Niraparib is an oral…”
Get more information

SENECA study: staging endometrial cancer based on molecular classification by Chacon, Enrique, Boria, Felix, Lyer, R Rajagopalan, Fanfani, Francesco, Malzoni, Mario, Bretová, Petra, Luzarraga Aznar, Ana, Fruscio, Robert, Jedryka, Marcin A, Tóth, Richard, Perrone, Anna Myriam, Kakkos, Athanasios, Cristóbal Quevedo, Ignacio, Congedo, Luigi, Zanagnolo, Vanna, Fernandez-Gonzalez, Sergi, Ferro, Beatriz, Narducci, Fabrice, Hovhannisyan, Tatevik, Aksahin, Elif, Cardenas, Laura, Oliver, M Reyes, Nozaleda, Gonzalo, Arnaez, Marta, Misiek, Marcin, Ferrero, Annamaria, Pain, Flore Anne, Zarragoitia, Janire, Diaz, Cristina, Ceppi, Lorenzo, Mehdiyev, Shamsi, Roldán-Rivas, Fernando, Guijarro-Campillo, Alberto Rafael, Amengual, Joana, Manzour, Nabil, Sanchez Lorenzo, Luisa, Núñez-Córdoba, Jorge M, Gonzalez Martin, Antonio, Minguez, Jose Angel, Chiva, Luis

“…Management of endometrial cancer is advancing, with accurate staging crucial for guiding treatment decisions. Understanding sentinel lymph node (SLN)…”
Get more information

Response of folliculotropic mycosis fungoides to capecitabine by Estenaga, Angela, Sanchez‐Lorenzo, Luisa, Antoñanzas‐Pérez, Javier, Morelló‐Vicente, Ana, Oteiza‐Rius, Inés, Cuns, Carolina Arean, Wells, Jillian, García‐Martínez, Francisco Javier

Get full text

Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising? by González‐Martín, Antonio, Sánchez‐Lorenzo, Luisa

“…Despite advances in surgery and chemotherapy and the integration of antivascular endothelial growth factor therapy as well as poly(adenosine…”
Get full text

Ansprechen follikulotroper Mycosis fungoides auf Capecitabin by Estenaga, Angela, Sanchez‐Lorenzo, Luisa, Antoñanzas‐Pérez, Javier, Morelló‐Vicente, Ana, Oteiza‐Rius, Inés, Cuns, Carolina Arean, Wells, Jillian, García‐Martínez, Francisco Javier

Get full text

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It by María Luque-Cabal, Paula García-Teijido, Yolanda Fernández-Pérez, Luisa Sánchez-Lorenzo, Isabel Palacio-Vázquez

“…The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of…”
Get full text

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine by Latzer, Pauline, Zelba, Henning, Battke, Florian, Reinhardt, Annekathrin, Shao, Borong, Bartsch, Oliver, Rabsteyn, Armin, Harter, Johannes, Schulze, Martin, Okech, Thomas, Golf, Alexander, Kyzirakos-Feger, Christina, Kayser, Simone, Pieper, Natalia, Feldhahn, Magdalena, Wünsche, Julian, Seitz, Christian, Hadaschik, Dirk, Garbe, Claus, Hauser, Till-Karsten, la Fougère, Christian, Biskup, Dirk, Brooke, Dawn, Parker, David, Martens, Uwe M., Illerhaus, Gerald, Blumenthal, Deborah T., Merrell, Ryan, Lorenzo, Luisa Sánchez, Hidvégi, Máté, de Robles, Paula, Kebir, Sied, Li, William W., Li, Vincent W., Williams, Matthew, Miller, Alexandra M., Kesari, Santosh, Castro, Michael, Desjardins, Annick, Ashley, David M., Friedman, Henry S., Wen, Patrick Y., Neil, Elisabeth C., Iwamoto, Fabio M., Sipos, Bence, Geletneky, Karsten, Zender, Lars, Glas, Martin, Reardon, David A., Biskup, Saskia

“…Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors…”
Get full text

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer by Jiménez-Fonseca, Paula, Carmona-Bayonas, Alberto, Sánchez Lorenzo, Maria Luisa, Plazas, Javier Gallego, Custodio, Ana, Hernández, Raquel, Garrido, Marcelo, García, Teresa, Echavarría, Isabel, Cano, Juana María, Rodríguez Palomo, Alberto, Mangas, Monserrat, Macías Declara, Ismael, Ramchandani, Avinash, Visa, Laura, Viudez, Antonio, Buxó, Elvira, Díaz-Serrano, Asunción, López, Carlos, Azkarate, Aitor, Longo, Federico, Castañón, Eduardo, Sánchez Bayona, Rodrigo, Pimentel, Paola, Limón, Maria Luisa, Cerdá, Paula, Álvarez Llosa, Renata, Serrano, Raquel, Lobera, Maria Pilar Felices, Alsina, María, Hurtado Nuño, Alicia, Gómez-Martin, Carlos

“…Background Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced…”
Get full text

Ansprechen follikulotroper Mycosis fungoides auf Capecitabin by Estenaga, Angela, Sanchez-Lorenzo, Luisa, Antoñanzas-Pérez, Javier, Morelló-Vicente, Ana, Oteiza-Rius, Inés, Cuns, Carolina Arean, Wells, Jillian, García-Martínez, Francisco Javier

Get full text

Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer by Sánchez-Lorenzo, Luisa, Bachiller, Alejandra, Gea, Claudia, Espinós, Jaime

“…Metastatic HER2-positive breast cancer remains a significant clinical challenge with a poor prognosis. The introduction of anti-HER2 therapies has…”
Get full text

The BRCA Gene in Epithelial Ovarian Cancer by Sánchez-Lorenzo, Luisa, Salas-Benito, Diego, Villamayor, Julia, Patiño-García, Ana, González-Martín, Antonio

“…Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. Germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2)…”
Get full text

SEOM-GEICO Clinical Guidelines on cervical cancer (2023) by Manso, Luis, Ramchandani-Vaswani, Avinash, Romero, Ignacio, Sánchez-Lorenzo, Luisa, Bermejo-Pérez, María José, Estévez-García, Purificación, Fariña-Madrid, Lorena, García García, Yolanda, Gil-Martin, Marta, Quindós, María

“…Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk…”
Get full text

First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions by González-Martín, Antonio, Sánchez-Lorenzo, Luisa, Bratos, Raquel, Márquez, Raúl, Chiva, Luis

“…Paclitaxel and carboplatin combination chemotherapy has remained the standard of care in the frontline therapy of advanced epithelial ovarian carcinoma during…”
Get full text

Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study by Munárriz, Javier, Reynés, Gaspar, Sánchez-Lorenzo, Luisa, Esteban, Emilio, Basterretxea, Laura, de Avila-Lizárraga, Leticia, Climent, Miguel Angel, Juan-Fita, María José, Escoín, Corina, Puente, Javier, Cassinello, Javier, Vázquez, Sergio, Chirivella, Isabel

“…Purpose The aim of this multicenter study was to evaluate the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib…”
Get full text

Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study by Garcia-Casado, Zaida, Oaknin, Ana, Mendiola, Marta, Alkorta-Aranburu, Gorka, Antunez-Lopez, Jose Ramon, Moreno-Bueno, Gema, Palacios, Jose, Yubero, Alfonso, Marquez, Raul, Gallego, Alejandro, Sanchez-Heras, Ana Beatriz, Lopez-Guerrero, Jose Antonio, Perez-Segura, Cristina, Barretina-Ginesta, Pilar, Alarcon, Jesus, Gaba, Lydia, Marquez, Antonia, Matito, Judit, Cueva, Juan, Palacio, Isabel, Iglesias, Maria, Arcusa, Angels, Sanchez-Lorenzo, Luisa, Guerra-Alia, Eva, Romero, Ignacio, Vivancos, Ana

“…Germline and tumor testing constitutes a valuable tool for clinical decision-making in the management of epithelial ovarian cancer (EOC) patients. Tissue…”
Get full text

On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry by Carmona-Bayonas, Alberto, Jiménez-Fonseca, Paula, Lorenzo, Maria Luisa Sánchez, Ramchandani, Avinash, Martínez, Elena Asensio, Custodio, Ana, Garrido, Marcelo, Echavarría, Isabel, Cano, Juana María, Barreto, Jose Enrique Lorenzo, García, Teresa García, Manceñido, Felipe Álvarez, Lacalle, Alejandra, Cardona, Marta Ferrer, Mangas, Monserrat, Visa, Laura, Buxó, Elvira, Azkarate, Aitor, Díaz-Serrano, Asunción, Montes, Ana Fernández, Rivera, Fernando

“…There is currently no consensus regarding first-line chemotherapy for patients with advanced gastric cancer (AGC) who are ineligible to receive trastuzumab…”
Get more information

Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC) by Alvarez-Fernandez, Carlos, Perez-Arnillas, Quionia, Ruiz-Echeverria, Lucrecia, Rodriguez-Rubi, David, Sanchez-Lorenzo, Luisa, Li-Torres, Walter, Izquierdo-Manuel, Marta, Berros, Jose P., Luque-Cabal, Maria, Jimenez-Fonseca, Paula, Villanueva-Palicio, Noemi, Esteban-Gonzalez, Emilio

“…Summary Introduction RFC is the major transport system in mammalian cells for folate cofactors and antifolate therapeutics. The aim of this study was to assess…”
Get full text

Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO by Yubero-Esteban, Alfonso, Barquin, Arantzazu, Gaba, Lydia, Iglesias Campos, Marcos, Reche-Molina, Piedad, Salvador Coloma, Carmen, Alarcon Company, Jesus, Manso, Luis, Marquez, Raul, Fuentes Pradera, Jose, Madani, Julia, Constenla Figueiras, Manuel, Gutierrez-Toribio, Maria, Estévez-García, Purificación, Santaballa, Ana, Sanchez Lorenzo, Maria Luisa, Calzas, Julia, Herrero, Ana, Taus, Alvaro, Gonzalez Martin, Antonio

“…e17562 Background: Rucaparib is a PARP inhibitor approved for the treatment of high-grade ovarian cancer (HGOC). Clinical trials have demonstrated its benefit…”
Get full text

Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO by Yubero-Esteban, Alfonso, Reche-Molina, Piedad, Salvador Coloma, Carmen, Estévez-García, Purificación, Manso, Luis, Iglesias Campos, Marcos, Barquin, Arantzazu, Marquez, Raul, Santaballa, Ana, Calzas, Julia, Herrero, Ana, Casado, Victoria, Madani, Julia, Merino, Maria, Marquina, Gloria, Alarcon Company, Jesus, Gaba, Lydia, Fuentes Pradera, Jose, Gonzalez Martin, Antonio, Sanchez Lorenzo, Maria Luisa

“…e17598 Background: Rucaparib is a PARP inhibitor (PARPi) approved as maintenance therapy for platinum (Pt)-sensitive recurrent high-grade ovarian cancer…”
Get full text

Immunotherapy - A paradigm shift in the treatment of cervical cancer by Sánchez Lorenzo, Luisa, Montero, L, Gallego, Alejandro, Vizcay, Ángel, González-Martín, Antonio

Get full text